Question to the Department for Science, Innovation & Technology:

To ask the Secretary of State for Science, Innovation and Technology, what mechanisms are in place to support collaboration between Government-funded bodies and private-sector researchers following the identification of multiple biological pathways implicated in ME by the LOCOME study.

The Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI), funds a broad portfolio of health research, including researcher led proposals using combinatorial genomic analysis. MRC has prioritised research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) for many years, investing over £4.65 million since 2020, and continues to welcome high quality applications in this area.

UKRI supports collaboration between Government funded bodies and private sector researchers across its councils and Innovate UK. This includes funding the LOCOME study led by Precision Life, through Innovate UK’s Advancing Precision Medicine programme, which supports the development of digital and data tools to improve diagnosis and treatment. MRC also enables academic-industry partnerships through its Industry Collaboration Framework.

UKRI does not typically maintain disease‑specific research strategies, instead providing open funding routes for the most impactful research across disciplines. Targeted work can be supported where needed. For example, in 2020, the National Institute for Health and Care Research (NIHCR), the Scottish Government and MRC funded the James Lind Alliance Priority Setting Partnership to identify ME/CFS research priorities.